Assessing the Effectiveness and Safety of Direct-acting Antiviral Treatment in Korean Patients with Hepatitis C Virus Genotype 1b or 2 at a Tertiary Care Hospital-Reference-Cited by-同舟云学术

Assessing the Effectiveness and Safety of Direct-acting Antiviral Treatment in Korean Patients with Hepatitis C Virus Genotype 1b or 2 at a Tertiary Care Hospital

Published:2022-09-30 Issue:3 Volume:32 Page:191-203
ISSN:1226-6051
Container-title:Korean Journal of Clinical Pharmacy
language:en
Short-container-title:Korean J Clin Pharm

Author:

Park Mi Seon¹²,Yang Young-Mo¹,Park Ki Hyun¹,Yoon Hyonok³,Kim Ju Sin²,Choi Eun Joo¹

Affiliation:

1. Department of Pharmacy, College of Pharmacy, Chosun University, Gwangju 61452, Republic of Korea

2. Department of Pharmacy, Jeonbuk National University Hospital, Jeonju 54907, Republic of Korea

3. Department of Pharmacy, Research Institute of Pharmaceutical Sciences, Gyeongsang National University, Jinju 52828, Republic of Korea

Publisher

The Korean College of Clinical Pharmacy

Subject

General Medicine

Link

http://pdf.medrang.co.kr/KJCP/2022/032/KJCP032-03-05.pdf

Reference30 articles.

1. World Health Organization. Hepatitis C (Newsroom/fact sheets). Available from http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed February 27, 2020.

2. World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C infection - July 2018. Available from https://www.who.int/publications/i/item/9789241550345. Accessed March 19, 2022.

3. World Health Organization. Global hepatitis report, 2017. Available from http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/. Accessed February 27, 2020.

4. Current status of hepatitis C virus infection and countermeasures in South Korea

5. Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C